THE DEAL, AT A GLANCE
From the announcementBlack Diamond Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedBlack Diamond Therapeutics raised $100M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersBlack Diamond Therapeutics is positioned around AI precision oncology for rare EGFR mutations not covered by existing drugs.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Black Diamond Therapeutics · Financing Record
Explore source-linked visual explanations for Black Diamond Therapeutics. Unsupported claims are withheld while source review continues.
Record 1117 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →